Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Endocrine Therapy in HR+ HER2- Breast Cancer
NCT03219476Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Feb 2017
- Primary completion
- Feb 2020
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of anastrozole, letrozole, exemestane, tamoxifen in invasive breast cancer, sponsored by Medical College of Wisconsin. Started Feb 2017; status: completed.
02
Drugs
anastrozoleletrozoleexemestanetamoxifen
03
Conditions
invasive breast cancer
Beyond the preview
Go deeper on NCT03219476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219476.